Table 2.

Identification of antibodies to high risk human papilloma viruses in prostate cancer. Case control serological studies with normal sera as controls

Study	Country	Prostate cancer	Controls	Main HPV types	P value
Dillner 1998 [52]	Finland	21/165 13%	36/290 12%	16,18,33	0.865 ns
Hisada 2000 [53]	US	20/48 42%	19/63 30%	16	0.253 ns
Hayes 2000 [54]	US	19/276 7%	15/295 5%	16	0.393 ns
Rosenblatt 2003 [55]	US	81/642 13%	64/570 11%	16,18	0.347 ns
Adami 2003 [56]	Sweden	69/238 29%	48/210 23%	16,18,33	0.212 ns
Korodi 2005 [57]	Sweden	107/799 13%	363/2596 14%	16,18,33	0.482 ns
Sutcliffe 2007 [58]	US	107/584 18%	114/577 20%	16,18,33	0.696 ns
Sitas 2007 [59]	South Africa	139/205 68%	390/673 58%	16	0.001 s
Huang 2008 [60]	US	154/868 18%	310/1283 24%	16,18	−0.002 s
Dennis 2009 [61]	US	50/267 19%	45/267 17%		0.637 ns
Sutcliffe 2010 [62]	US	23/616 4%	22/616 4%	16,18,31	0.686 ns
Chen 2011 [12]	Australia	29/53 55%	41/104 39%	16,18,31,33,52,58	0.131 ns
Hrbacek 2011 [63]	Czech	167/316 53%	69/101 68%	16,18,31,33	−0.161 ns
Tachezy 2012 [28]	Czech	14/50 28%	37/173 22%	16,18,31,33	0.445 ns
Zhao 2017 [64]	China	48/75 64%	14/80 17.5%	16	0.001 s

s = significant at p = 0.05. ns = not significant